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Newcastle upon Tyne, United KingdomBackground: Clusters of rare cylindroma or spiradenoma tumors are a recurrent clinical presentation, yet
conventional genetic testing results in individuals with these tumors are frequently normal.Objective: To determine if genetic mosaicism accounts for such cases.Methods: A study of 6 cases from a series of 55 patients who met criteria for diagnostic gene testing for
pathogenic CYLD variants over a 5-year period (2012-2017) was performed. A novel genetic assay was used
to study DNA from peripheral blood leukocytes and, where possible, matched skin and tumor tissue.Results: Two patients had mosaic pathogenic CYLD variants in both the blood and skin. One of these
patients transmitted a pathogenic variant to her daughter, and we report the novel phenotype of a
contiguous gene deletion syndrome involving CYLD. Two patients had recurrent pathogenic variants in
skin tumors from a single cluster but none detectable in the blood.Limitations: The remaining 2 patients had clinical features of mosaicism, but these cases were not solved
with the assays used because of a lack of access of fresh tumor tissue.Conclusion: Genetic mosaicism should be considered in patients presenting with clustered cylindromas,
because this may inform genetic testing and counseling of these patients. ( J Am Acad Dermatol https://
doi.org/10.1016/j.jaad.2019.05.021.)
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YLD cutaneous syndrome (CCS), also called
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ated with large rearrangements,6 intronic variants
affecting splicing,7 and large deletions8 in isolated
case reports. However, the remaining cases are
unexplained, presenting a challenge for genetic
counseling of affected individuals.
Postzygotic mutation resulting in mosaicism mayCAPSULE SUMMARY
d Clusters of asymmetric cylindromas are a
clinical indicator of underlying genetic
mosaicism.
d In such patients who lack a family
history, genetic testing of skin tumors is
necessary. This is relevant for genetic
counseling because these patients can
transmit a more severe form of the
disease to their children.account for some of these
unexplained cases. It is sug-
gested clinically by affected
individuals who develop
CCS tumors in an asymmetric
distribution, typically clus-
tered or in a linear array on
the scalp or torso.9-14
Postzygotic mutation of
genes affecting keratinocytes
during embryonic develop-
ment can result in skin con-
ditions that follow Blaschko’s
lines.15 CCS tumors have
been reported to manifest in
a Blaschko-linear pattern14;
however, mosaic pathogenic CYLD variants have
not been previously shown in such cases.9
CCS is a dominantly inherited skin tumor syn-
drome.2 CYLD encodes a ubiquitin hydrolase
enzyme involved in the posttranslational modifica-
tion deubiquitination.16-19 By removing ubiquitin
chains from relevant protein substrates, CYLD nor-
mally negatively regulates cell signaling pathways
that are implicated in tumor formation, such as
nuclear factor kB, Wnt, and transforming growth
factoreb.2 In patients with familial CCS, germline
heterozygous pathogenic CYLD variants reported
within the catalytic residues of CYLD are frequently
truncating,20 predicting loss of function. CCS tumors
typically have a ‘‘second hit’’ that affects the remain-
ing normal copy of CYLD, resulting in loss of
heterozygosity (LOH).21 We posited that postzygotic
CYLD mutations could occur during embryonic
development, with subsequent LOH in affected cells
leading to mosaic presentations of CCS tumors.
In this study, we investigated this hypothesis in
patients with clustered tumors who fit clinical criteria
for diagnostic testing of CYLD22 but lacked a patho-
genic CYLD variant detectable via Sanger sequencing
of coding exons in a peripheral blood sample. By
using novel genetic assays to study blood and tumor
tissue in these patients, we show the existence of
postzygotic mutations resulting in mosaicism in
patients with clusters of CCS tumors. We also
document transmission from a parent with mosaic
CCS to a child, underscoring the clinical relevance of
obtaining a genetic diagnosis in these cases.METHODS
Ethics
Regulatory approvals were sought and obtained
from a human subjects ethics review board
(National Research Ethics Service Committee
North East-Tyne and Wear, reference no. 14/NE/
1080;06/1059).Sample collection
Consenting patients sup-
plied blood samples for
DNA analysis. Fresh-frozen
tissue or RNAlater-stored
material (RNAlater solution,
Life Technologies, Grand
Island, NY) was also available
in some cases.
DNA and RNA extraction
Genomic DNA was ex-
tracted from fresh-frozen tis-
sue and peripheral blood with
the DNeasy Tissue kit(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. RNA was extracted from trial samples
and control samples as previously described.23
Genetic assays
We used a long-range polymerase chain reaction
(PCR) assay coupled with next-generation sequencing
(NGS) to investigate the entire 56-kilobase genomic
locus of CYLD with an average on-target sequencing
depth of greater than 20003 (here after referred to as
long-range PCR [LR-PCR]). Briefly, 8 amplicons ranging
from 6 to 8 kilobase in size were designed to cover the
promoter, coding exons, and introns of CYLD. Primer
sequences and PCR conditions are available on
request. Findings were validated by using NGS of
affected amplicons or, in selected cases in which the
minor allele frequency was greater than 0.2, Sanger
sequencing of amplicons. In 2 tumors for case 4, RNA
sequencing data were used for pathogenic CYLD
variant detection. In 3 tumors for case 4, single-
nucleotide polymorphism (SNP) arrays were used to
detect large deletions.
RESULTS
We reviewed 55 patients who met criteria22 for
diagnostic gene testing for pathogenic CYLD vari-
ants. After Sanger sequencing of coding exons of
CYLD from peripheral leukocyte DNA, 39 cases were
deemed to carry pathogenic CYLD variants. From the
16 mutation-negative cases, we included 5 patients
with a single localized cluster of CCS tumors and 1
Abbreviations used:
CCS: CYLD cutaneous syndrome
LOH: loss of heterozygosity
Mb: megabase
NGS: next-generation sequencing
PCR: polymerase chain reaction
PGD: preimplantation genetic diagnosis
SNP: single-nucleotide polymorphism
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presentation is also compatible with mosaicism
(Table I and Fig 1, A and B). The patients with
localized clusters had 2 to 8 tumors, which ranged
from 3mm to 3 cm in diameter. The clusters were 3 to
8 cm in size, with constituent lesions in direct
apposition or up to 4 cm apart. Five of the 6 patients
with clustered tumors had no family history of CCS.
In the 10 remaining patients without clustered
tumors, 3 had a positive family history result.
Mosaic CYLD point mutation in the blood and
skin as a cause of asymmetric CCS
On LR-PCR, case 1 showed 8% mutant reads of a
previously reported24 pathogenic variant in CYLD
present in the blood. Analysis of tumor tissue from 2
samples from this patient by Sanger sequencing
clearly showed this variant, present at a minor allele
frequency of more than 80%, indicative of LOH. LR-
PCR analysis did not show a mosaic pathogenic
CYLD variant in the blood in the other 5 cases.
Mosaic CYLD mutation in the skin alone as a
cause of asymmetric CCS
In case 2 (Fig 1, A), 2 tumors developed at the age
of 70 years and grew progressively on the left side of
the vertex of the scalp. Both tumor samples showed
an identical 25ebase pair deletion in exon 19 of
CYLD, with LOH. We also analyzed interlesional
normal-appearing skin using the same approach
and detected the same pathogenic CYLD variant in
a very low percentage of sequence reads in normal-
appearing skin (18/5886 reads; 0.31%), and, notably,
this variant was not evident in a peripheral leukocyte
and a buccal DNA sample. Case 3 reported multiple
localized tumors presenting from the 3rd decade.
Two separate tumors were analyzed, and an iden-
tical frameshift pathogenic CYLD variant in exon 11
with LOH of CYLD was detected in both tumors.
Mosaic large deletions in the blood and skin as
a cause of CCS
In case 4, 20 cylindromas had developed since the
age of 30 years, with bilateral clusters seen on the
forehead. Five distinct pathogenic CYLD variantswere found in 5 tumors, with 1 in each tumor
(Table I). Results of SNP array analysis of the blood
were normal, ruling out a heterozygous germline
deletion. However, because SNP arrays are unable to
detect low-level mosaicism in blood, we performed
SNP arrays on DNA from 3 of the 5 tumors, in which
such mosaic deletions would be clonally amplified.
This showed an identical 5.5-megabase (Mb) dele-
tion encompassing CYLD and 23 other genes in all 3
tumors at a minor allele frequency of approximately
80%.Transmission of mosaic CCS from parent to
child and the phenotype of a contiguous
deletion syndrome involving CYLD
We proceeded to investigate the daughter of case
4 (Fig 2, A), who hadmild intellectual disability and a
single kidney from birth but did not have cylindro-
mas when examined in her 30s. She had mild
dysmorphic facial features, including anteverted
nares, a long philtrum, retroverted small ears, and
mild retrognathia. SNP array analysis of peripheral
lymphocyte DNA showed the presence of the het-
erozygous germline 5.5-Mb deletion seen in her
mother’s tumors (Fig 2, B). Interrogation of the
DECIPHER database (a public database of DNA
microarray and sequencing data of children with
developmental disorders) showed an additional 7
cases who carried a deletion including CYLD in the
germline.25 Three of these patients had renal hypo-
plasia, 5 had intellectual disability, and 1 had a skin
tumor. Additional recurrent features reported
include abnormality of the pinnae, anal atresia, and
hypospadias in males.Clinical features of mosaicism in unsolved
cases
Case 5, who did not have a family history of CCS,
reported a single tumor appearing on the scalp in his
50s and 2more tumors appearing on the same side of
the scalp when he was in his 60s. The clinical
presentation was consistent with a postzygotic mu-
tation affecting CYLD. Only paraffin-embedded
tumor tissue was available, precluding the use of
LR-PCR. Sanger sequencing of coding exons was
successful in 40% of coding exons but inconclusive
in the remainder. Case 6 had a single localized cluster
of tumors (Fig 1, A) and a family history of CCS
affecting 3 generations. The clinical presentationwas
consistent with the combination of a germline and a
postzygotic mutation affecting CYLD. A germline
deletion was excluded by using an SNP array.
Tumor tissue was not available for genetic analysis
in this case.
Table I. Clinical cases of mosaic CCS deemed mutation-negative after Sanger sequencing of coding exons
Case
Age at onset
of skin
tumors, years
Family
history Phenotype Blood (NGS or array) Skin tumor
CYLD tumor variant and ACGS
classification (LOH)*
1 30s NEG Single localized cluster of
cylindromas (n[ 5)
8% mutant reads 2 tumors, truncating variant exon
19
c.2806C[T p.(Arg936*)
Pathogenic
2 70s NEG Single localized cluster of
cylindromas (n = 2)
Normal NGS results 2 tumors, 25-bp deletion exon 19 (c.2499_2524del
p.(His833Glnfs*48)
Likely pathogenic
3 30s NEG Single localized cluster of
cylindromas (n = 4)
Normal
NGS results
2 tumors, frameshift variant exon
11
(c.1520_1527delinsCTGTACAGAA;
p.(Glu507fs)
Pathogenic
4 30s NEG Bilateral clusters of cylindromas;
3 tumors had features of
cylindrospiradenoma (n[ 20)
Normal NGS and
array results
5 tumors, diverse single-nucleotide
variants; recurrent 5.5-Mb
deletion in tumors 1-3.
Tumor 1: c.1912G[T p.(Glu638*)
Pathogenic
Tumor 2: c.1808T[G p.(Leu603*)
Pathogenic
Tumor 3: c.1821dupA
p.(Phe608Ilefs*7)
Pathogenic
Tumor 4: c.1112C[A p.(Ser371*)
Pathogenic
Tumor 5: c.2158G[A p.(Glu720Lys)
Likely pathogenic
5 50s NEG Single localized cluster of
cylindromas; biopsy results
showed 1 tumor had features
of cylindrospiradenoma (n = 3)
Normal
NGS results
NDy NDy
6 50s POS Single localized cluster of
cylindromas (n = 8)
Normal NGS and
array results
Not examined Not examined
ACGS, Association for Clinical Genomic Science; LOH, loss of heterozygosity in all cases with reported variants; ND, no data; NEG, negative family history of cylindromas; NGS, long-range PCR
targeting the CYLD locus coupled with next-generation sequencing; POS, positive family history of cylindromas.
*CYLD mutations are annotated according to RefSeq: NM_015247.
yComprehensive analysis of all coding exons was not feasible because of the technical limitations of studying DNA derived from paraffin-embedded tissue.
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Fig 1. Mosaic CYLD cutaneous syndrome. A, Localized clusters of cylindroma or cylindrospir-
adenoma shown, from left to right, in cases 2, 5, and 6. B, Histopathology of cylindroma
(hematoxylin-eosin stain; original magnification: 20). White scale bar indicates 50 m.
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In this study, we found clustered cylindromas or
cylindrospiradenomas in 6 of 16 mutation-negative
cases of CCS; in 4 of these, we found novel molecular
evidence of genetic mosaicism. The rarity of CCS
tumors in the general population makes the devel-
opment of asymmetric clustered CCS tumors
(including trichoepitheliomas) a flag that shouldlead the physician to consider a diagnosis of mosaic
CCS. In CCS, in which tumors predominantly man-
ifest on the scalp, asymmetric clustered presenta-
tions may be masked by hair, and careful clinical
examination is warranted.
Patients with mosaic CCS should have their
genetic testing tailored depending on their family
history. Patients with a postzygotic mutation alone
Fig 2. CYLD contiguous deletion syndrome. A, The facial gestalt of the daughter with a
germline contiguous gene deletion involving CYLD. B, The 5.5-Mb deletion, indicated within
the double-ended red arrows, was validated in the child as present in a heterozygous state and
involved CYLD and 23 additional genes.
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negative result from Sanger sequencing of CYLD in
a blood sample (unless the level of leukocyte
mosaicism is [40%). A negative result should
prompt analysis of DNA from at least 2 skin tumor
samples, optimally from noneparaffin-embedded
tissue. The presence of a recurring pathogenic
CYLD variant detectable in multiple skin tumors
within this cluster supports mosaicism, and this
information can be used in genetic testing ofchildren or in preimplantation genetic diagnosis
(PGD). A caveat is that mosaic tumors may occur in
more than 1 cluster and can have a bilateral distri-
bution, as shown by case 4. Hence, cases deemed
mutation-negative by Sanger sequencing with bilat-
eral clustered tumors may also benefit from this
approach, particularly if they lack a parental history
of CCS. It should also be considered that some
mosaic cases with high levels of mosaicism may
mimic the phenotype of germline cases.
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asymmetric cluster of tumors are expected to have a
postzygotic second-hit CYLD mutation within these
lesions in addition to the familial germline CYLD
variant.26 Sanger sequencing of blood leukocyte
DNA alone can yield an answer in these patients,
unless they have a genetic mutation that prevents
PCR amplification of themutant allele, such as a large
deletion, inversion, or rearrangement involving
CYLD. As the cost of NGS decreases, whole-
genome sequencing of blood is likely to be increas-
ingly adopted in diagnostic settings. This has the
advantage of overcoming the limitations of PCR, with
the potential to detect mosaicism, providing there is
sufficient coverage and sequencing depth of the
CYLD locus.
A further informative point in case 4 is the finding
of 5 distinct pathogenic CYLD variants in 5 tumors,
with a large deletion involving the other allele. This
finding suggests that the complete deletion of CYLD
alone may be insufficient for the formation of
cylindromas, which is reminiscent of phenotypic
findings in CYLD mouse models, in which homozy-
gous CYLD deletion results in a normal mouse at
birth27; however, transgenic mice expressing homo-
zygous truncating patient mutations die at birth.28
Future work to study the differential effects of
deletions and truncating mutations in CYLD on
tumorigenesis may help explain our research find-
ings in case 4.
The importance of finding the pathogenic CYLD
variant in mosaic cases is emphasized by our report
of transmission of a pathogenic CYLD variant from a
mosaic parent to the germline of a child. In this case,
and in others recorded in DECIPHER, the clinical
phenotype of the heterozygous contiguous gene
deletion is more complex and severe than the mosaic
form. Notably, skin tumors are not frequently re-
ported in the DECIPHER series, which may reflect
the early age at which these cases are studied,
typically in the first years of life. We suggest that
the presentation of cylindroma, or a family history of
cylindromas, together with intellectual disability
and/or renal abnormalities should alert the clinician
to consider a contiguous gene-deletion syndrome.
The risk to a mosaic CCS parent carrying a post-
zygotic mutation of conceiving a germline-affected
child cannot, currently, be accurately estimated,
although DNA analysis of sperm in males may
help. Otherwise, PGD, or other prenatal diagnostic
strategies, may be considered in mosaic individuals
who plan to start a family, once the pathogenic CYLD
variant is known. The selection of PGD, which
carries attendant risks, may be influenced by the
level of mosaicism in the affected parent.Our method has limitations. The LR-PCR assay we
report is able to detect mosaic exonic, intronic, and
promoter changes within the CYLD locus, which is
an advantage over Sanger sequencing of coding
exons. However, it is unable to detect large de-
letions, gene fusions, and inversions, and these
explanations may account for the lack of a molecular
diagnosis in case 6. We determined 3 cases to have
mosaicism in the skin alone using our assay by
studying blood DNA; however, we cannot exclude
the possibility of rare mutant cells that are below the
threshold of detection of our assay. As such, there is
still a theoretical risk of transmission, albeit small,
that can be excluded only by PGD. We did not seek
to determine the lower limit of detection of our assay
in this study, and this limit would be required to
implement this assay in a diagnostic setting.CONCLUSIONS
Our findings have pragmatic implications for
genetic investigation of mutation-negative CCS
cases. The selection of assays will vary from center
to center and be influenced by resource and
sequencing infrastructure but must be able to detect
mosaicism in mutation-negative CCS cases. Our
findings are relevant to other skin tumor syndromes
in which linear or clustered tumors such as basal cell
carcinomamay occur.29,30 We emphasize the need to
analyze affected tumor tissue31 from these patients if
blood proves to be mutation-negative to identify
genetic mosaicism, which confers a risk of trans-
mission to offspring.
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